Â鶹ѧÉú¾«Æ·°æ

Skip to main content
Randy L. Jensen
( out of 85 reviews )

Randy L. Jensen, MD, PhD

Languages spoken: English, Japanese

Clinical Locations

Clinical Neurosciences Center

Salt Lake City
801-585-7575

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Neurology
Salt Lake City
801-585-0260
  • Dr. Randy Jensen specializes in Neurosurgery, Brain Tumors, Skull Base Surgery, Neuro Trauma and Neurocritical Care. He has a particular emphasis using preoperative imaging, intraoperative navigation, intraoperative cortical mapping and intraoperative MRI to maximize tumor resection and minimize surgical complications. He treats patients with malignant, benign, and metastatic brain tumors. He has many clinical trials for patients with brain tumors and has a laboratory effort examining brain tumor biology. He is also a member of the Brain Tumor Research Team at Huntsman Cancer Institute.

    Board Certification

    American Board of Neurological Surgery (Neurosurg)

    Patient Rating

    4.9 /5
    ( out of 85 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 20, 2024
    HUNTSMAN CANCER CENTER

    Dr. Jensen was very thorough and very knowledgeable about my case. He made me feel like he cared as did my family also

    October 17, 2024
    HUNTSMAN CANCER CENTER

    He was fantastic to meet and talk to. He had already reviewed everything about me, so I could ask him anything and he could keep up. He smiled and chuckled a lot. He and his staff were wonderful and I felt right at ease. Almost hates to leave. Almost.

    October 17, 2024
    HUNTSMAN CANCER CENTER

    Randy is an amazing Doctor and I'm thrilled he was the one to do my brain surgery the care I have received each time I come in to visit is amazing. I know he truly cares about his patients.

    October 13, 2024
    HUNTSMAN CANCER CENTER

    Dr. Jensen was very helpful in explaining what's going to happen when I have my radiation on my brain

    September 22, 2024
    HUNTSMAN CANCER CENTER

    Dr. Randy Jensen is one of the best doctors around. He cares about his patients and takes the time necessary to make them feel like they are in good hands. I should know, he saved my life!!!

    September 21, 2024
    HUNTSMAN CANCER CENTER

    He is a good Doctor, he is a nice person.

    July 12, 2024
    HUNTSMAN CANCER CENTER

    I am so grateful for Dr. Jensen. From the moment I met him, I knew I was going to be ok. He is an excellent surgeon.

    June 27, 2024
    HUNTSMAN CANCER CENTER

    Dr Jensen and staff are amazing, thoughtful and very thorough. We're very grateful for their knowledge and capable hands that have me a longer life and better outlook on life.

    June 27, 2024
    HUNTSMAN CANCER CENTER

    Great professional with a positive attitude.

  • Dr. Randy Jensen specializes in Neurosurgery, Brain Tumors, Skull Base Surgery, Neuro Trauma and Neurocritical Care. He has a particular emphasis using preoperative imaging, intraoperative navigation, intraoperative cortical mapping and intraoperative MRI to maximize tumor resection and minimize surgical complications. He treats patients with malignant, benign, and metastatic brain tumors. He has many clinical trials for patients with brain tumors and has a laboratory effort examining brain tumor biology. He is also a member of the Brain Tumor Research Team at Huntsman Cancer Institute.

    Board Certification and Academic Information

    Academic Departments Neurosurgery -Primary
    Oncological Sciences -Adjunct
    Radiation Oncology -Adjunct
    Board Certification
    American Board of Neurological Surgery (Neurosurg)

    Education history

    Fellowship Â鶹ѧÉú¾«Æ·°æcare, Academy of Health Science Educators Fellow
    Neurosurgery - University of Illinois MHPE
    Doctoral Training Loyola University Medical Center Ph.D.
    Neurosurgery - Loyola University of Chicago Resident
    Professional Medical Medicine - University of Utah Hospital School of Medicine M.D.
    Chemistry - University of Utah B.A.
    Undergraduate Biology - University of Utah B.S.

    Selected Publications

    Journal Article

    1. Cole KL, Earl ER, Findlay MC, Sherrod BA, Tenhoeve SA, Kunzman J, Cannon DM, Akerley W, Burt L, Seifert SB, Goldman M, Jensen RL (2024). Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era. J Neurooncol, 169(3), 671-681. ()
    2. Gravbrot N, Rock CB, Weil CR, Rock CB, Burt LM, DeCesaris CM, Jensen RL, Shrieve DC, Cannon DM (2024). Gross tumor and intracranial control benefits with fractionated radiotherapy compared to stereotactic radiosurgery for patients with WHO grade 2 meningioma. World Neurosurg, 188, e259-e266. ()
    3. Michalopoulos GD, Katsos K, Grills IS, Warnick RE, McInerney J, Attia A, Timmerman R, Chang E, Andrews DW, DAmbrosio AL, Cobb WS, Pouratian N, Spalding AC, Walter K, Jensen RL, Bydon M, Asher AL, Sheehan JP (2023). Stereotactic radiosurgery in the management of non-small cell lung cancer brain metastases: a prospective study using the NeuroPoint Alliance Stereotactic Radiosurgery Registry. J Neurosurg, 140(5), 1223-1232. ()
    4. Underhill HR, Karsy M, Davidson CJ, Hellwig S, Stevenson S, Goold EA, Vincenti S, Sellers DL, Dean C, Harrison BE, Bronner MP, Colman H, Jensen RL (2024). Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas. Cancer Res, 84(7), 1149-1164. ()
    5. Rock CB, Weil CR, Rock CB, Gravbrot N, Burt LM, DeCesaris C, Menacho ST, Jensen RL, Shrieve DC, Cannon DM (2024). Patterns of failure after radiosurgery for WHO grade 1 or imaging defined meningiomas: Long-term outcomes and implications for management. J Clin Neurosci, 120, 175-180. ()
    6. Robinson LJ, Goold E, Potter S, Quigley EP, Jensen RL, Mao Q (2024). A pleomorphic xanthoastrocytoma highlighting the morphological heterogeneity of this uncommon tumor. J Neuropathol Exp Neurol, 83(1), 61-64. ()
    7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2023). Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol, 41(32), 4945-4952. ()
    8. Earl ER, Colman H, Mendez J, Jensen RL, Karsy M (2023). An evaluation of biobanking and therapeutic clinical trial representation among adult glioma patients from rural and urban Utah. Neurooncol Pract, 10(5), 472-481. ()
    9. Gamboa NT, Crabb B, Henson JC, Cole KL, Weaver BD, Karsy M, Jensen RL (2022). High-grade glioma imaging volumes and survival: a single-institution analysis of 101 patients after resection using intraoperative MRI. J Neurooncol, 160, 555-565. ()
    10. Jensen RL, Dunson B, Richards B, Park YS, Hirshfield LE (2022). A Longitudinal, Qualitative Examination of Participant Intent-To-Change Statements that do not Match the Stated Learning Objectives of American Association of Neurological Surgeons-Sponsored Continuing Medical Education Activities. World Neurosurg, 167, e1325-e1334. ()
    11. Tatman PD, Wroblewski TH, Fringuello AR, Scherer SR, Foreman WB, Damek DM, Youssef AS, Lillehei KO, Jensen RL, Graner MW, Ormond DR (2022). High-Throughput Screening of Epigenetic Inhibitors in Meningiomas Identifies HDAC, G9a, and Jumonji-Domain Inhibition as Potential Therapies. J Neurol Surg B Skull Base, 84(5), 452-462. ()
    12. Yahanda AT, Rich KM, Dacey RG Jr, Zipfel GJ, Dunn GP, Dowling JL, Smyth MD, Leuthardt EC, Limbrick DD Jr, Honeycutt J, Sutherland GR, Jensen RL, Evans J, Chicoine MR (2022). Survival After Resection of Newly-Diagnosed Intracranial Grade II Ependymomas: An Initial Multicenter Analysis and the Logistics of Intraoperative Magnetic Resonance Imaging. World Neurosurg, 167, e757-e769. ()
    13. Nguyen S, Cole KL, Timme KH, Jensen RL (2022). Development of a residents-as-teachers curriculum for neurosurgical training programs. Neurosurg Focus, 53(2), E6. ()
    14. Jensen RL, Lipsman N, Amin-Hanjani S, Haglund MM (2022). Introduction. Education methodology and metrics in the training of neurosurgical residents. Neurosurg Focus, 53(2), E1. ()
    15. Kundu B, Brock AA, Garry JG, Jensen RL, Burt LM, Cannon DM, Shrieve DC, Rolston JD (2022). Outcomes using linear accelerator stereotactic radiosurgery for the treatment of trigeminal neuralgia: A single-center, retrospective study. Surg Neurol Int, 13, 246. ()
    16. Hunsaker JC, Herring L, Franklin S, Christensen KB, Chan B, Jensen RL (2022). The path to neurosurgery: identifying obstacles to pursuing a medical career unique to rural high school students when compared with urban and suburban students. J Neurosurg, 137(6), 1866-1871. ()
    17. Lehman NL, Spassky N, Sak M, Webb A, Zumbar CT, Usubalieva A, Alkhateeb KJ, McElroy JP, Maclean KH, Fadda P, Liu T, Gangalapudi V, Carver J, Abdullaev Z, Timmers C, Parker JR, Pierson CR, Mobley BC, Gokden M, Hattab EM, Parrett T, Cooke RX, Lehman TD, Costinean S, Parwani A, Williams BJ, Jensen RL, Aldape K, Mistry AM (2022). Astroblastomas exhibit radial glia stem cell lineages and differential expression of imprinted and X-inactivation escape genes. Nat Commun, 13(1), 2083. ()
    18. Tatman PD, Wroblewski TH, Fringuello AR, Scherer SR, Foreman WB, Damek DM, Lillehei KO, Jensen RL, Youssef AS, Ormond DR, Graner MW (2022). Targeting DNA Methyl Transferases with Decitabine in Cultured Meningiomas. World Neurosurg, 162, e99-e119. ()
    19. Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm AL (2022). A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer, 3(2), 232-250. ()
    20. Dunson B, Park YS, Richards B, Hirshfield LE, Jensen RL (2021). Longitudinal Comparison of Continuing Medical Education Learning Objectives and Intent-to-Change Statements of Participants. J Contin Educ Health Prof, 42(4), 236-242. ()
    21. Schupper AJ, Baron RB, Cheung W, Rodriguez J, Kalkanis SN, Chohan MO, Andersen BJ, Chamoun R, Nahed BV, Zacharia BE, Kennedy J, Moulding HD, Zucker L, Chicoine MR, Olson JJ, Jensen RL, Sherman JH, Zhang X, Price G, Fowkes M, Germano IM, Carter BS, Hadjipanayis CG, Yong RL (2021). 5-Aminolevulinic acid for enhanced surgical visualization of high-grade gliomas: a prospective, multicenter study. J Neurosurg, 136(6), 1525-1534. ()
    22. Tatman PD, Wroblewski TH, Fringuello AR, Scherer SR, Foreman WB, Damek DM, Lillehei K, Youssef AS, Jensen RL, Graner MW, Ormond DR (2021). High-Throughput Mechanistic Screening of Epigenetic Compounds for the Potential Treatment of Meningiomas. J Clin Med, 10(14). ()
    23. Kim RB, Scoville JP, Karsy M, Lim S, Jensen RL, Menacho ST (2021). Work relative value units and perioperative outcomes in patients undergoing brain tumor surgery. Neurosurg Rev, 45, 719-728. ()
    24. Jensen RL, Kestle JRW, Brockmeyer DL, Couldwell WT (2020). Principles of Remediation for the Struggling Neurosurgery Resident. World Neurosurg, 146, e1118-e1125. ()
    25. Yahanda AT, Patel B, Shah AS, Cahill DP, Sutherland G, Honeycutt J, Jensen RL, Rich KM, Dowling JL, Limbrick DD, Dacey RG, Kim AH, Leuthardt EC, Dunn GP, Zipfel GJ, Leonard JR, Smyth MD, Shah MV, Abram SR, Evans J, Chicoine MR (2020). Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study. Neurosurgery, 88(1), 63-73. ()
    26. Shah AS, Yahanda AT, Sylvester PT, Evans J, Dunn GP, Jensen RL, Honeycutt J, Cahill DP, Sutherland GR, Oswood M, Shah M, Abram SR, Rich KM, Dowling JL, Leuthardt EC, Dacey RG, Kim AH, Zipfel GJ, Limbrick DD, Smyth MD, Leonard J, Chicoine MR (2019). Using Histopathology to Assess the Reliability of Intraoperative Magnetic Resonance Imaging in Guiding Additional Brain Tumor Resection: A Multicenter Study. Neurosurgery, 88(1), E49-E59. ()
    27. Shah AS, Sylvester PT, Yahanda AT, Vellimana AK, Dunn GP, Evans J, Rich KM, Dowling JL, Leuthardt EC, Dacey RG, Kim AH, Grubb RL, Zipfel GJ, Oswood M, Jensen RL, Sutherland GR, Cahill DP, Abram SR, Honeycutt J, Shah M, Tao Y, Chicoine MR (2020). Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. J Neurosurg, 1-10. ()
    28. Pedersen BS, Bhetariya PJ, Brown J, Kravitz SN, Marth G, Jensen RL, Bronner MP, Underhill HR, Quinlan AR (2020). Somalier: rapid relatedness estimation for cancer and germline studies using efficient genome sketches. Genome Med, 12(1), 62. ()
    29. Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol, 148(3), 577-585. ()
    30. Ponnapalli SP, Bradley MW, Devine K, Bowen J, Coppens SE, Leraas KM, Milash BA, Li F, Luo H, Qiu S, Wu K, Yang H, Wittwer CT, Palmer CA, Jensen RL, Gastier-Foster JM, Hanson HA, Barnholtz-Sloan JS, Alter O (2020). Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival. APL Bioeng, 4(2), 026106. ()
    31. Yahanda AT, Patel B, Sutherland G, Honeycutt J, Jensen RL, Smyth MD, Limbrick DD Jr, Dacey RG Jr, Dowling JL, Dunn GP, Kim AH, Leuthardt EC, Rich KM, Zipfel GJ, Leonard JR, Cahill DP, Shah MV, Abram SR, Evans J, Tao Y, Chicoine MR (2019). A Multi-Institutional Analysis of Factors Influencing Surgical Outcomes for Patients with Newly Diagnosed Grade I Gliomas. World Neurosurg, 135, e754-e764. ()
    32. Tiburcio PDB, Gillespie DL, Jensen RL, Huang LE (2020). Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential. J Neurooncol, 146(3), 427-437. ()
    33. Bounajem MT, Karsy M, Jensen RL (2019). Liquid biopsies for the diagnosis and surveillance of primary pediatric central nervous system tumors: a review for practicing neurosurgeons. Neurosurg Focus, 48(1), E8. ()
    34. Burnett BA, Womeldorff MR, Jensen R (2020). Meningioma: Signaling pathways and tumor growth. Handb Clin Neurol, 169, 137-150. ()
    35. Weaver BD, Goodman JR, Jensen R (2019). Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review. Cureus, 11(11), e6147. ()
    36. Smith N, Saunders D, Jensen RL, Towner RA (2019). Association of decreased levels of lipopolysaccharide-binding protein with OKN-007-induced regression of tumor growth in an F98 rat glioma model. J Neurosurg, 1-9. ()
    37. Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM (2019). Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight, 4(20). ()
    38. Sherrod BA, Gamboa NT, Wilkerson C, Wilde H, Azab MA, Karsy M, Jensen RL, Menacho ST (2019). Effect of patient age on glioblastoma perioperative treatment costs: a value driven outcome database analysis. J Neurooncol, 143(3), 465-473. ()
    39. Zhang XC, Lipman J, Jensen R, Parekh K (2019). Thematic Analysis of Emergency Medicine Applicants' Personal Statements. Med Sci Educ, 29(3), 659-665. ()
    40. Ronna B, Guan J, Karsy M, Service J, Ekins A, Jensen R (2019). A Survey of Neurosurgery Residency Program Coordinators: Their Roles, Responsibilities, and Perceived Value. Cureus, 11(4), e4457. ()
    41. Yang I, Udawatta M, Prashant GN, Lagman C, Bloch O, Jensen R, Sheehan J, Kalkanis S, Warnick R (2018). Stereotactic Radiosurgery for Neurosurgical Patients: A Historical Review and Current Perspectives. World Neurosurg, 122, 522-531. ()
    42. Yang I, Udawatta M, Prashant GN, Preet K, Mekonnen M, Duong C, Sheppard JP, Nguyen T, Bloch O, Jensen R, Sheehan J, Kalkanis S, Warnick RE (2018). Commentary: Stereotactic Radiosurgery Training for Neurosurgery Residents: Results of a Survey of Residents, Attendings, and Program Directors by the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors. Neurosurgery, 84(1), E86-E91. ()
    43. Karsy M, Burnett B, Di Ieva A, Cusimano MD, Jensen RL (2018). Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome. J Neurosurg, 128(3), 657-666. ()
    44. Guan J, Brock AA, Karsy M, Couldwell WT, Schmidt MH, Kestle JRW, Jensen RL, Dailey AT, Schmidt RH (2017). Managing overlapping surgery: an analysis of 1018 neurosurgical and spine cases. J Neurosurg, 127(5), 1096-1104. ()
    45. Jensen RL, Alzhrani G, Kestle JRW, Brockmeyer DL, Lamb SM, Couldwell WT (2017). Neurosurgeon as educator: a review of principles of adult education and assessment applied to neurosurgery. J Neurosurg, 127(4), 949-957. ()
    46. Bagshaw HP, Burt LM, Jensen RL, Suneja G, Palmer CA, Couldwell WT, Shrieve DC (2017). Adjuvant radiotherapy for atypical meningiomas. J Neurosurg, 126(6), 1822-1828. ()
    47. Huang LE, Cohen AL, Colman H, Jensen RL, Fults DW, Couldwell WT (2017). IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget, 8(1), 191-202. ()
    48. Bagshaw HP, Ly D, Jensen RL, and Shrieve DC (2016). Local control after stereotactic radiosurgery for melanoma brain metastases by metastatic lesion. J Radiosurg SBRT, 4, 181-190.
    49. Kalinina J, Ahn J, Devi NS, Wang L, Li Y, Olson JJ, Glantz M, Smith T, Kim EL, Giese A, Jensen RL, Chen CC, Carter BS, Mao H, He M, Van Meir EG (2016). Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. Clin Cancer Res, 22(24), 6256-6265. ()
    50. Hu N, Richards R, Jensen RL (2016). Role of chromosone 1p/19q co-deletion on the prognosis of oliogodendromagliomas: A systemic review and meta-analysis. Interdiscip Neurosurg, 5, 58-63.
    51. Karsy M, Hoang N, Barth T, Burt L, Dunson W, Gillespie DL, Jensen RL (2016). Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. World Neurosurg, 86, 210-9. ()
    52. de Souza PC, Balasubramanian K, Njoku C, Smith N, Gillespie DL, Schwager A, Abdullah O, Ritchey JW, Fung KM, Saunders D, Jensen RL, Towner RA (2015). OKN-007 decreases tumor necrosis and tumor cell proliferation and increases apoptosis in a preclinical F98 rat glioma model. J Magn Reson Imaging, 42(6), 1582-91. ()
    53. Jensen RL (2015). Predicting Outcomes After Glioma Surgery: Model Behavior. World Neurosurg, 84(4), 894-6. ()
    54. Lloyd IE, Clement PW, Salzman KL, Jensen RL, Salama ME, Palmer CA (2015). An unusual and challenging case of HIV-associated primary CNS Lymphoma with Hodgkin-like morphology and HIV encephalitis. Diagn Pathol, 10(1), 152. ()
    55. Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve DC (2015). Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg, 123(2), 395-401. ()
    56. Karsy M, Sivakumar W, Neil J, Guan J, Moy F, Jensen RL (2015). Meta-analysis of the effect of isocitrate dehydrogenase 1 and 2 mutation on glioblastoma prognosis. Contemp Neurosurg, 37(5), 1-6.
    57. Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang LE (2015). Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. PLoS One, 10(4), e0125125. ()
    58. Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus, 38(3), E4. ()
    59. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus, 38(3), E2. ()
    60. Gillespie DL, Aguirre MT, Ravichandran S, Leishman LL, Berrondo C, Gamboa JT, Wang L, King R, Wang X, Tan M, Malamas A, Lu ZR, Jensen RL (2014). RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model. J Neurosurg, 122(2), 331-41. ()
    61. Gillespie DL, Arce-Larreta MT, Ravichandran S, Leishman LL, Berrondo C, Gamboa J, Wang L, Wang X, Lu Z-R, Jensen RL (2015). RNA interference targeting HIF-1a via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model. J Neurosurg, 122(2), 331-341.
    62. Womeldorff M, Gillespie D, Jensen RL (2014). Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma. Neurosurg Focus, 37(6), E8. ()
    63. Kent T, Jensen RL (2014). Intraoperative Magnetic Resonance Imaging in Neurosurgery: Part II -- Brain Shift, Perioperative Complications, and Costs. Contemp Neurosurg, 36(23).
    64. Kent T, Jensen RL (2014). Intraoperative Magnetic Resonance Imaging in Neurosurgery: Part 1 -- A Review of History, Use, and Outcomes. Contemp Neurosurg, 36(23).
    65. Jensen RL, Mumert ML, Gillespie DL, Kinney AY, Schabel MC, Salzman KL (2014). Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol, 16(2), 280-91. ()
    66. Terakedis BE, Jensen RL, Shrieve DC (2014). Tumor Control and incidence of radiation necrosis after reirradiation with stereotactic radiosurgery for bran metastases. (3), 21-28.
    67. Ghia A, Jensen RL, Sherieve A, Hu N, Li X, Shrieve D (2014). Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. (3), 43-50.
    68. Wagner AE, Chen A, Jensen RL, Shrieve DC (2014). Stereotactic radiosurgery for solitary brain metastases: Factors impacting control. J Radiosurg SBRT, 3(2), 111-121.
    69. Jensen RL (2014). Educating our residents for the alphabet soup of PQRS and HCAHPS. 23(4).
    70. Schabel MC, DiBella EV, Jensen RL, Salzman KL (2010). A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: II. In vivo results. Phys Med Biol, 55(16), 4807-23. ()
    71. Anker CJ, Hymas RV, Hazard LJ, Boucher KM, Jensen RL, Shrieve DC (2010). Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme. J Neurooncol, 98(2), 253-63. ()
    72. Mumert ML, Walsh MT, Jensen EM, Jensen RL (2009). Pleomorphic liposarcoma originating from intracranial dura mater. J Neurooncol, 97(1), 149-53. ()
    73. Ragel BT, Couldwell WT, Gillespie DL, Jensen RL (2007). Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis. Neurosurg Rev, 30(3), 181-7; discussion 187. ()

    Review

    1. Khan M, Hanna C, Findlay M, Lucke-Wold B, Karsy M, Jensen RL (2023). Modeling Meningiomas: Optimizing Treatment Approach. [Review]. Neurosurg Clin N Am, 34(3), 479-492. ()
    2. Hu N, Cheng H, Zhang K, Jensen R (2017). Evaluating the Prognostic Accuracy of Biomarkers for Glioblastoma Multiforme Using The Cancer Genome Atlas Data. [Review]. Cancer Inform, 16, 1176935117734844. ()
    3. Karsy M, Guan J, Cohen AL, Jensen RL, Colman H (2017). New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. [Review]. Curr Neurol Neurosci Rep, 17(2), 19. ()
    4. Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. [Review]. Neurosurg Clin N Am, 27(2), 249-60. ()

    Edited Book

    1. Zada G, Jensen RL (Eds.) (April 2016). Neurosurgery Clinics of North America.
    2. G Zada, RL Jensen (Eds.) (2015). Neurosurgery Clinics of North America.

    Book Chapter

    1. Abou Al-Shaar H, Jensen RL, Couldwell WT (2020). Primary central nervous system lymphoma. In R Nader, A Sabbagh, SK Elbabaa, H Al-Jehani, J Gasco, C Gragniello (Eds.), Neurosurgery Case Review: Questions and Answers (2nd edition). New York: Thieme.
    2. Weaver BD, Jensen RL (2018). Hemangiopericytoma. In Lonser R, Elder B (Eds.), Cases in Surgical Neuro-oncology. New York: Oxford University Press.
    3. Weaver BD, Jensen RL (2017). Posterior fossa metastases. In Couldwell WT (Ed.), Skull Base Surgery of the Posterior Fossa. New York: Springer.

    Case Report

    1. Ravindra VM, Braca JA 3rd, Jensen RL, Duckworth EA (2015). Management of intracranial pathology during pregnancy: Case example and review of management strategies. Surg Neurol Int, 6, 43. ()
    2. Mazur MD, Neil JA, Agarwal C, Jensen RL, Couldwell WT (2015). Surgical management of a transosseous meningioma with invasion of torcula, superior sagittal sinus, transverse sinus, calvaria, and scalp. Surg Neurol Int, 6, 40. ()

    Editorial

    1. Jensen RL, Zada G (2023). Meningiomas: An Update on Diagnostic and Therapeutic Approaches. Neurosurg Clin N Am, 34(3), xiii. ()
    2. Amin-Hanjani S, Bambakidis NC, Barker FG, Carter BS, Cockroft KM, Du R, Fraser JF, Hamilton MG, Huang J, Jane JA, Jensen RL, Kaplitt MG, Kaufmann AM, Pilitsis JG, Riina HA, Schulder M, Vogelbaum MA, Yang LJS, Zada G (2020). Editorial. COVID-19 and neurosurgical practice: an interim report. J Neurosurg, 1-2. ()
    3. Zada G, Jensen RL (2016). Meningiomas: An Update on Diagnostic and Therapeutic Approaches. Neurosurg Clin N Am, 27(2), xiii. ()
    4. Jensen RL (2014). Navigated transcranial magnetic stimulation: another tool for preoperative planning for patients with motor-eloquent brain tumors. Neuro Oncol, 16(10), 1299-300. ()

    Abstract

    1. Frandsen J, Orton A, Shrieve DS, Jensen RL, Colman H, Cohen H, Tward J, and Suneja G (2016). U.S. patterns of care and outcomes for gliosarcoma; a National Cancer Database Project [Abstract]. Int J Radiat Oncol Biol Phys, 96(2 suppl), E96.

    Other

    1. Lehman NL, Spassky N, Sak M, Webb A, Zumbar CT, Usubalieva A, Alkhateeb KJ, McElroy JP, Maclean KH, Fadda P, Liu T, Gangalapudi V, Carver J, Abdullaev Z, Timmers C, Parker JR, Pierson CR, Mobley BC, Gokden M, Hattab EM, Parrett T, Cooke RX, Lehman TD, Costinean S, Parwani A, Williams BJ, Jensen RL, Aldape K, Mistry AM (2023). Author Correction: Astroblastomas exhibit radial glia stem cell lineages and differential expression of imprinted and X-inactivation escape genes. Nat Commun (14(1), p. 507). England. ()